To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD

This is an interventional treatment trial for Pulmonary Disease, Chronic Obstructive focused on measuring TRELEGY ELLIPTA, Single Inhaler, Fluticasone Furoate, Umeclidinium Bromide, Vilanterol, FF/UMEC/VI Read More

Inclusion Criteria:

• Participant must be 40 years or above of age inclusive, at the time of signing the informed consent.
• Participants with a documented physician diagnosis of COPD.
• CAT greater than or equal to (≥) 10.
• Existing COPD Maintenance Treatment. Participants currently receiving one of the maintenance therapies given below who have been prescribed it continually for at least 12 weeks prior to screening (Visit 1): Inhaled Corticosteroids/ Long-Acting Beta-2-Agonists (ICS/LABA) (single or multiple inhalers); Long-Acting Muscarinic Antagonist (LAMA)/LABA (single or multiple inhalers); Free combination of inhaled corticosteroids (ICS), LAMA, LABA.
• Current or former cigarette smokers with a history of cigarette smoking history ≥10 pack-years at screening.
• Trelegy is prescribed under the discretion of clinical physicians with medical records providing documentation of a Trelegy prescription in daily practice.
• Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion Criteria:

• Women who are pregnant or lactating or are planning on becoming pregnant during the study.
• Prescribed with Trelegy within one year prior to screening (Visit 1).
• Participants who, in the opinion of the treating investigator, are chronic users of oral corticosteroids for respiratory or other indications (if unsure discuss with the medical monitor prior to screening). Chronic use is defined as more than 14 days continuous use during the 12 weeks prior to Visit 1.
• Participants with any life-threatening condition i.e. low probability, in the opinion of the investigator, of 3-month survival due to severity of COPD or comorbid condition.
• Participants with unstable COPD. Participants with resolution of an exacerbation less than 2 weeks prior to Visit 1. Participants may be rescreened 2 weeks after resolution of exacerbation (exacerbation is defined as: requiring treatment with antibiotics and/or systemic steroids or hospitalization; resolution is defined as: 2 weeks after all symptoms have resolved and any medicines to treat the exacerbation have finished).
• Participants who need more than 3 liter per minute (L/min) supplemental oxygen at rest at screening.
• Other diseases/abnormalities: Participants with historical or current evidence of uncontrolled or clinically significant disease. Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the participant at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.
• Participant received any investigational drug in other clinical trial within four weeks or 5 half-lives prior to this study whichever is longer.
• Any conditions or illnesses listed in the section of contraindications in the Summary of Product Characteristics (SmPC) of Trelegy, i.e., hypersensitivity to the active substances of TRELEGY ELLIPTA.
• Participants with known COVID-19 positive contacts within the past 14 days.
• Inability to read: In the opinion of the Investigator, any participant who is unable to read and/or would not be able to complete study related materials.